STO-CSCO Joint Symposium 2017

Continuing to build on the vibrant partnership of STO and CSCO, this symposium will be featured during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 26 – 30, 2017.

Translated Articles

《肿瘤学家》精选论文
Read translations of selected articles targeting practice issues relevant to Chinese clinicians.

Browse All Topics

The Oncologist in China

《肿瘤学家》中国项目概览
Download a 2-page pdf overview of The Oncologist’s Clinical Trial Results section information.

Video Library

视频库
Watch the latest presentations from the STO First Advisory Council: LUNG CANCER: A Grand Challenge for Public Health & Education.

Past Meetings

Welcome to 'The Oncologist' in China

Recent Translated Articles from The Oncologist

Volume 22, Number 6, June 2017


Clinical Trial Results

Ramucirumab治疗中国晚期实体瘤患者的I期剂量递增研究
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
Junning Cao, Dongmei Ji, Zhiyu Chen, Weina Shen, Jin Wang, Baoyue Li, Haidong Chi, Amanda Long, Ling Gao, Jin Li
The Oncologist 2017; 22:638-e56; first published on May 2, 2017; doi:10.1634/theoncologist.2017-0137

卡铂联合每周一次白蛋白结合型紫杉醇改良方案治疗非小细胞肺癌老年患者的II期研究:日本北部肺癌研究组1301试验
Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose
The Oncologist 2017; 22:640-e59; first published on May 19, 2017; doi:10.1634/theoncologist.2017-0059

Breast Cancer

双重抗HER2治疗用于HER2阳性乳腺癌新辅助治疗的心脏安全性
Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer
Anthony F. Yu, Jasmeet C. Singh, Rui Wang, Jennifer E. Liu, Anne Eaton, Kevin C. Oeffinger, Richard M. Steingart, Clifford A. Hudis, Chau T. Dang
The Oncologist 2017; 22:642-647; first published on March 24, 2017; doi:10.1634/theoncologist.2016-0406

内分泌治疗在绝经后雌激素受体阳性转移性乳腺癌治疗中的应用现状
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
Daniele Generali, Filippo Montemurro, Roberto Bordonaro, Antonino Mafodda, Sante Romito, Andrea Michelotti, Pierluigi Piovano, Maria Teresa Ionta, Claudia Bighin, Donata Sartori, Antonio Frassoldati, Marina Elena Cazzaniga, Ferdinando Riccardi, Franco Testore, Patrizia Vici, Carlo Antonio Barone, Alessio Schirone, Federico Piacentini, Franco Nolè, Annamaria Molino, Luciano Latini, Edda Lucia Simoncini, Fausto Roila, Francesco Cognetti, Francesco Nuzzo, Jennifer Foglietta, Alessandro Marco Minisini, Francesca Goffredo, Giuseppe Portera, Gilda Ascione, Gabriella Mariani
The Oncologist 2017; 22:648-654; first published on April 21, 2017; doi:10.1634/theoncologist.2016-0461

遗传性乳腺癌综合征患者的全身治疗策略
Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes
Amanda Parkes, Banu K. Arun, Jennifer K. Litton
The Oncologist 2017; 22:655-666; first published on May 3, 2017; doi:10.1634/theoncologist.2016-0430

Gastrointestinal Cancer

标准新辅助放化疗无效的局部晚期直肠癌患者接受全身化疗挽救治疗
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy
Francesco Sclafani, Gina Brown, David Cunningham, Sheela Rao, Paris Tekkis, Diana Tait, Federica Morano, Chiara Baratelli, Eleftheria Kalaitzaki, Shahnawaz Rasheed, David Watkins, Naureen Starling, Andrew Wotherspoon, Ian Chau
The Oncologist 2017; 22:728-736; first published on May 5, 2017; doi:10.1634/theoncologist.2016-0396

Lung Cancer

中性粒细胞-淋巴细胞比值可作为接受过综合治疗的局部晚期(IIIA和IIIB期)非小细胞肺癌患者的预后标志物
Neutrophil‐Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non‐Small Cell Lung Cancer Treated with Combined Modality Therapy
Katherine A. Scilla, Søren M. Bentzen, Vincent K. Lam, Pranshu Mohindra, Elizabeth M. Nichols, Melissa A. Vyfhuis, Neha Bhooshan, Steven J. Feigenberg, Martin J. Edelman, Josephine L. Feliciano
The Oncologist 2017; 22:737-742; first published on May 22, 2017; doi:10.1634/theoncologist.2016-0443


Volume 22, Number 5, May 2017


Clinical Trial Results

一项醋酸阿比特龙与PI3K/mTOR双重抑制剂BEZ235联合治疗转移性去势抵抗性前列腺癌的I期研究
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei, Andrew C. Hsieh, Won Kim, Terence Friedlander, Amy M. Lin, Mirela Louttit, Charles J. Ryan
The Oncologist 2017; 22:503-e43; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0432

索拉非尼(BAY 43-9006)治疗卡波西肉瘤患者的Ib期研究
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
Thomas S. Uldrick, Priscila H. Gonçalves, Kathleen M. Wyvill, Cody J. Peer, Wendy Bernstein, Karen Aleman, Mark N. Polizzotto, David Venzon, Seth M. Steinberg, Vickie Marshall, Denise Whitby, Richard F. Little, John J. Wright, Michelle A. Rudek, William D. Figg, Robert Yarchoan
The Oncologist 2017; 22:505-e49; first published on March 24, 2017; doi:10.1634/theoncologist.2016-0486

Breast Cancer

内分泌治疗在绝经后雌激素受体阳性转移性乳腺癌治疗中的应用现状
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor‐Positive Metastatic Breast Cancer
Virginia G. Kaklamani, William J. Gradishar
The Oncologist 2017; 22:507-517; first published on March 17, 2017; doi:10.1634/theoncologist.2015-0464

SAFE-HEaRt:一项在左心室功能降低的HER2阳性乳腺癌患者中评价HER2靶向治疗的心脏安全性的初步研究 - 原理和设计
SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left Ventricular Function
Filipa Lynce, Ana Barac, Ming T. Tan, Federico M. Asch, Karen L. Smith, Chau Dang, Claudine Isaacs, Sandra M. Swain
The Oncologist 2017; 22:518-525; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0412

根据中期18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描显示的完全代谢缓解预测乳腺癌患者接受新辅助化疗后的长期生存情况
Complete Metabolic Response on Interim 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long‐Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Suyun Chen, Nuhad K. Ibrahim, Yuanqing Yan, Stephen T. Wong, Hui Wang, Franklin C. Wong
The Oncologist 2017; 22:526-534; first published on April 4, 2017; doi:10.1634/theoncologist.2016-0334

Hepatobiliary

使用预后列线图对无门静脉癌栓的肝细胞癌患者行根治切除术后的生存期进行分层
Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection
Yi‐Peng Fu, Yong Yi, Jin‐Long Huang, Chu‐Yu Jing, Jian Sun, Xiao‐Chun Ni, Zhu‐Feng Lu, Ya Cao, Jian Zhou, Jia Fan, Shuang‐Jian Qiu
The Oncologist 2017; 22:561-569; first published on April 24, 2017; doi:10.1634/theoncologist.2016-0231

No front page content has been created yet.

 

The Oncologist and the Society for Translational Oncology (STO) partner with the Chinese Society of Clinical Oncology (中国抗癌协会临床肿瘤学协作专业委员会, CSCO) and the CSCO Foundation (中国临床肿瘤学会基金会) on educational initiatives that address critical health and cancer care issues in China. These efforts serve to foster communication between Chinese physicians and other leaders in oncology practice throughout the world.